Richard P. Baum-Yantai Lannacheng Biotechnology Co., Ltd.

Richard P. Baum

Chief Medical Advisor of LNC

Professor of Nuclear Medicine, University Frankfurt-Main, Germany

President, International Centers for Precision Oncology (ICPO)

Chairman of the Advanced Theranostic Centre for Radiomolecular Precision Oncology at CURANOSTICUM, Wiesbaden-Frankfurt, Germany

Research interest: radioligand theranostics, precision molecular targeted therapy of neuroendocrine tumors, prostate cancer, and various solid tumors.

President (2013), World Association of Radionuclide and Molecular Therapy (WARMTH). President of the International Research Group in Immunoscintigraphy and Immunotherapy (IRIST).

Co-founder of the Theranostics World Congress (TWC).

Received multiple awards, including the Saul Hertz Award (2019) and the Agasthiar Award (2011)

The first radioimmunotherapy performed in Germany (1985), the first peptide receptor therapy in Germany (1997), and the first 177Lu-based PSMA radioligand therapy in the world (2013).

Published over 700 peer-reviewed papers.